Coya Therapeutics Inc. (COYA) News
Filter COYA News Items
COYA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
COYA News Highlights
- For COYA, its 30 day story count is now at 8.
- Over the past 14 days, the trend for COYA's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- RDY, ROSS and SA are the most mentioned tickers in articles about COYA.
Latest COYA News From Around the Web
Below are the latest news stories about COYA THERAPEUTICS INC that investors may wish to consider to help them evaluate COYA as an investment opportunity.
Mr. Wilbur L. Ross, Former United States Secretary of Commerce, Joins Board of Coya Therapeutics, Inc.HOUSTON, December 20, 2023--Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced that it has appointed Secretary Wilbur Ross to its board of directors, effective immediately. Coya intends to leverage Secretary Ross’s extensive experience in both the business and investment community to help guide strategic partnering activitie |
David Einhorn's Greenlight Capital Adds Coya Therapeutics to Its PortfolioRenowned investment firm Greenlight Capital, led by David Einhorn (Trades, Portfolio), has recently expanded its investment portfolio with the acquisition of shares in Coya Therapeutics Inc (NASDAQ:COYA). On December 12, 2023, the firm added 810,959 shares to its holdings, reflecting a significant commitment to the biotechnology company. |
David Einhorn's Greenlight Capital Boosts Coya Therapeutics HoldingFirm real-time pick highlight |
Coya Therapeutics’ CEO Dr. Howard Berman’s Letter to StockholdersHOUSTON, December 13, 2023--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today released the following letter to stockholders from its Chief Executive Officer and Chairman, Dr. Howard Berman. |
Coya Therapeutics Announces Closing of $26.5 Million Private PlacementHOUSTON, December 12, 2023--Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of regulatory T cells ("Tregs"), announced today the closing of the sale of an aggregate of 4,370,382 shares of its common stock at a purchase price of $6.06 per share of common stock, in a private placement priced at-the-market under Nasdaq rules. |
Dr. Reddy's (RDY), COYA Ink Deal to Develop COYA 302 for ALSDr. Reddy's (RDY) enters into a licensing agreement with Coya Therapeutics to develop and commercialize the latter's ALS investigational combination therapy, COYA 302. |
Coya Therapeutics Announces $26.5 Million Private PlacementHOUSTON, December 06, 2023--Coya Therapeutics, Inc. (Nasdaq:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of regulatory T cells ("Tregs"), announced today that it has entered into definitive securities purchase agreements for the purchase and sale of an aggregate of 4,370,382 shares of its common stock at a purchase price of $6.06 per share of common stock, in a private placement priced at-the-mark |
Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)HOUSTON & HYDERABAD, India & BASEL, Switzerland, December 06, 2023--Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy’s"), and Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya"), today announced that they have entered into a development and license agreement (the "Agreement") for the development and commercialization of COYA 302, an investigatio |
Coya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial ResultsHOUSTON, November 08, 2023--Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced its financial results for the third quarter ended September 30, 2023, and provided a clinical and business update. |
Coya Announces Acceptance of Oral Presentation, "Regulatory T Cell Expansion Strategy to Target Inflammation in Alzheimer’s Disease: A Phase 1 Feasibility Study," at the 18th International Conference on Alzheimer’s and Parkinson’s Disease in LisbonHOUSTON, October 27, 2023--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today announced that Dr. Alireza Faridar, Assistant Professor of Neurology at Houston Methodist and Weill Cornell Medical College, will give an oral presentation at the 18th International Conference on Alzheimer’s and Parkinson’s Disease held in Lisbo |